JP4409295B2 - Ptx3遺伝子発現抑制方法 - Google Patents
Ptx3遺伝子発現抑制方法 Download PDFInfo
- Publication number
- JP4409295B2 JP4409295B2 JP2003583400A JP2003583400A JP4409295B2 JP 4409295 B2 JP4409295 B2 JP 4409295B2 JP 2003583400 A JP2003583400 A JP 2003583400A JP 2003583400 A JP2003583400 A JP 2003583400A JP 4409295 B2 JP4409295 B2 JP 4409295B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- groups
- expression
- gene expression
- ptx3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101150095640 PTX3 gene Proteins 0.000 title claims description 21
- 230000014509 gene expression Effects 0.000 title abstract description 31
- 238000000034 method Methods 0.000 title abstract description 7
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims description 9
- 229940122498 Gene expression inhibitor Drugs 0.000 claims description 7
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 6
- 229960002797 pitavastatin Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 150000002596 lactones Chemical class 0.000 abstract description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 7
- 125000000217 alkyl group Chemical class 0.000 abstract description 7
- 125000000962 organic group Chemical group 0.000 abstract description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract description 2
- 101150090724 3 gene Proteins 0.000 abstract 2
- -1 pyrazolopyridyl group Chemical group 0.000 description 17
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 8
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 8
- 229960003296 pitavastatin calcium Drugs 0.000 description 8
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 6
- 229960001770 atorvastatin calcium Drugs 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 3
- 102100036202 Serum amyloid P-component Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 108700025763 PTX3 Proteins 0.000 description 1
- 101710192097 Pentraxin-related protein PTX3 Proteins 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000041715 pentraxin family Human genes 0.000 description 1
- 108091075331 pentraxin family Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
従って、PTX3遺伝子の発現を抑制することにより、自己免疫疾患、特に慢性関節リウマチの進行が抑制され、更には治療に繋がるが、しかしこれまで、IFN−γ、TGF−β以外に、PTX3遺伝子の発現を抑制する物質は、全く知られていない。
Breviarioら:J. Biol. Chem., 267(31),22190-7(1992) Leeら:J. Immunol., 150(5), 1804-12(1993) J. Biol. Chem., 267(31),22190-7(1992);動脈硬化, 24(7-8),375-80(1996) Circulation, 102, 636-41(2000) Arterioscler. Thromb. Vasc. Biol., 22,782-7(2002) Clin. Exp. Immunol., 119(1),196-202(2000) J. Biol. Chem., 272(52),32817-23(1997)
すなわち、本発明は、次式(1)
また、本発明は、上記式(1)で表わされる化合物、そのラクトン誘導体又はそれらの塩及び薬学的に許容される担体を含有するPTX3遺伝子発現抑制剤組成物を提供するものである。
また、本発明は、上記式(1)で表わされる化合物、そのラクトン誘導体又はそれらの塩のPTX3遺伝子発現抑制剤の製造のための使用を提供するものである。
環構造を有する有機基としては、インドリル基、インデニル基、ピリジル基、ピロロピリジル基、ピラゾロピリジル基、チエノピリジル基、ピリミジル基、ピラゾリル基、ピロリル基、イミダゾリル基、インドリジル基、キノリル基、ナフチル基、ヘキサヒドロナフチル基、シクロヘキシル基、フェニルシリルフェニル基、フェニルチエニル基及びフェニルフリル基が挙げられ、特にヘキサヒドロナフチル基、インドリル基、ピリジル基、ピリミジル基、ピロリル基及びキノリル基が好ましい。
またこのような種々の剤型の医薬製剤を調製するには、この有効成分を単独で、又は他の1種以上の薬学的に許容される賦形剤、結合剤、増量剤、崩壊剤、界面活性剤、滑沢剤、分散剤、緩衝剤、保存剤、嬌味剤、香料、被膜剤、担体、希釈剤等を適宜組み合わせて用いることができる。
正常ヒト臍帯静脈内皮細胞(HUVEC)又はヒト冠状動脈平滑筋細胞(HCASMC)を3×105cells/10cm dishに蒔いた2日後に、ピタバスタチンカルシウム又はアトルバスタチンカルシウムを、それぞれ1.1μmol/L、6.6μmol/Lになるように添加した。コントロールには、両有効成分の溶媒であるジメチルスルホキシド(終濃度0.0066v/v%)を添加した。添加8時間後に、ISOGEN(商標、日本ジーン社製)を用いて全RNAを抽出した。以下の操作は、Affymetrix社の使用手順書に従った。すなわち、得られた全RNAより常法に従い、mRNAを精製し、このmRNAを元にcDNAを合成した。さらにin vitro転写によりビオチン標識cRNAを合成し、精製した後、熱処理により断片化し、遺伝子発現解析に用いた。
HUVECにおいて有効成分添加8時間後のPTX3遺伝子の発現は、コントロールでは発現量で1113.0であるのに対し、ピタバスタチンカルシウム、アトルバスタチンカルシウム添加群ではそれぞれ32.7、39.2と有意に抑制された。さらにHCASMCにおいても、有効成分添加8時間後のPTX3遺伝子の発現は、コントロールでは発現量で1028.3であるのに対し、ピタバスタチンカルシウム、アトルバスタチンカルシウム添加群ではそれぞれ452.5、432.1と有意に抑制された。
HUVECを3×105cells/10cm dishに蒔いた2日後に、ピタバスタチンカルシウム、アトルバスタチンカルシウムを、それぞれ1.1μmol/L、6.6μmol/Lになるように添加した。また、ピタバスタチンのPTX3遺伝子発現抑制作用における濃度依存性を評価する目的で、HUVEC又はHCASMCを3×105cells/10cm dishに蒔いた2日後に、ピタバスタチンカルシウムを1μmol/L、10μmol/Lになるように添加した。なおコントロールには、各々の条件において、両有効成分の溶媒であるジメチルスルホキシド(終濃度0.0066v/v%)を添加した。添加8又は24時間後に、ISOGEN(商標、日本ジーン社製)を用いて全RNAを抽出した。得られた全RNAを、常法に従いRT−PCRに処し、増幅したDNA断片をアガロースゲル電気泳動し、遺伝子発現量を比較した。
RT反応:RNA PCR Core Kit(商標、Roche Molecular Systems社製)を用いて行った。
PCR:ExpandTM High Fidelity PCR system(商標、Boehringer Mannheim社製)を用い、95℃1分−57℃1分−72℃1分を25サイクル行った。なおPCRプライマーとして、以下のセットを用いた。PTX3の場合は配列番号1(Forward)及び配列番号2(Reverse);GAPDHの場合は配列番号3(Forward)及び配列番号4(Reverse)を用いた。
HUVECにおいてPTX3遺伝子の発現は、ピタバスタチンカルシウムあるいはアトルバスタチンカルシウムの添加により、8時間後、24時間後共にコントロールに比べて抑制された。またHUVEC及びHCASMCにおいてPTX3遺伝子の発現は、ピタバスタチンカルシウムの添加により、8時間後、24時間後共に濃度依存的に抑制された。
Claims (2)
- ピタバスタチン又はその塩を有効成分として含有するPTX3遺伝子発現抑制剤。
- ピタバスタチン又はその塩、及び薬学的に許容される担体を含有するPTX3遺伝子発現抑制剤組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37211402P | 2002-04-15 | 2002-04-15 | |
US10/196,428 US20030195167A1 (en) | 2002-04-15 | 2002-07-17 | PTX3-gene expression inhibitor |
PCT/JP2003/004603 WO2003086380A1 (en) | 2002-04-15 | 2003-04-11 | Ptx3 gene expression suppressing method |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005522490A JP2005522490A (ja) | 2005-07-28 |
JP2005522490A5 JP2005522490A5 (ja) | 2006-02-09 |
JP4409295B2 true JP4409295B2 (ja) | 2010-02-03 |
Family
ID=28794074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003583400A Expired - Fee Related JP4409295B2 (ja) | 2002-04-15 | 2003-04-11 | Ptx3遺伝子発現抑制方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20030195167A1 (ja) |
EP (1) | EP1494661B1 (ja) |
JP (1) | JP4409295B2 (ja) |
AT (1) | ATE445395T1 (ja) |
AU (1) | AU2003226456A1 (ja) |
DE (1) | DE60329668D1 (ja) |
MY (1) | MY137134A (ja) |
TW (1) | TWI349547B (ja) |
WO (1) | WO2003086380A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276486A1 (en) * | 2003-04-17 | 2006-12-07 | Kowa Co., Ktd. | Lklf/klf2 gene expression promoter |
US8415364B2 (en) | 2003-11-26 | 2013-04-09 | Duke University | Method of preventing or treating glaucoma |
ITRM20030596A1 (it) * | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
JP4667372B2 (ja) * | 2004-02-25 | 2011-04-13 | 株式会社ペルセウスプロテオミクス | 血管障害の程度の判定方法 |
EP1740164B1 (en) * | 2004-04-26 | 2008-08-13 | Alcon Inc. | Statins for the treatment of ocular hypertension and glaucoma |
WO2008001499A1 (fr) * | 2006-06-29 | 2008-01-03 | Kowa Co., Ltd. | Agent prophylactique et/ou thérapeutique pour le traitement de la polyarthrite rhumatoïde |
CN106950366B (zh) * | 2017-02-15 | 2019-03-22 | 中国医学科学院北京协和医院 | 一种acpa阴性的ra诊断标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244916A (en) * | 1992-01-31 | 1993-09-14 | The Scripps Research Institute | Inhibition of respiratory burst using posttranslational modification inhibitors |
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
JP2002539108A (ja) * | 1999-03-08 | 2002-11-19 | メルク エンド カムパニー インコーポレーテッド | 結晶質水和ジヒドロキシオープンアシッドシンバスタチンカルシウム塩 |
US6403637B1 (en) * | 1999-08-09 | 2002-06-11 | Univ Saint Louis | Methods of modulating matrix metalloproteinase activity and uses thereof |
US20030018040A1 (en) * | 2000-02-10 | 2003-01-23 | Yasuo Sugiyama | Tnf-alpha inhibitors |
AU2002210521A1 (en) * | 2000-09-19 | 2002-04-02 | Novimmune S.A. | Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
US20020159974A1 (en) * | 2000-09-19 | 2002-10-31 | Francois Mach | Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors) |
-
2002
- 2002-07-17 US US10/196,428 patent/US20030195167A1/en not_active Abandoned
-
2003
- 2003-04-08 MY MYPI20031287A patent/MY137134A/en unknown
- 2003-04-11 AT AT03746454T patent/ATE445395T1/de not_active IP Right Cessation
- 2003-04-11 EP EP03746454A patent/EP1494661B1/en not_active Expired - Lifetime
- 2003-04-11 JP JP2003583400A patent/JP4409295B2/ja not_active Expired - Fee Related
- 2003-04-11 DE DE60329668T patent/DE60329668D1/de not_active Expired - Lifetime
- 2003-04-11 TW TW092108385A patent/TWI349547B/zh not_active IP Right Cessation
- 2003-04-11 AU AU2003226456A patent/AU2003226456A1/en not_active Abandoned
- 2003-04-11 WO PCT/JP2003/004603 patent/WO2003086380A1/en active Application Filing
-
2007
- 2007-03-30 US US11/694,288 patent/US20080161348A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60329668D1 (de) | 2009-11-26 |
AU2003226456A8 (en) | 2003-10-27 |
ATE445395T1 (de) | 2009-10-15 |
AU2003226456A1 (en) | 2003-10-27 |
WO2003086380A1 (en) | 2003-10-23 |
JP2005522490A (ja) | 2005-07-28 |
MY137134A (en) | 2008-12-31 |
TWI349547B (en) | 2011-10-01 |
EP1494661B1 (en) | 2009-10-14 |
TW200403990A (en) | 2004-03-16 |
US20080161348A1 (en) | 2008-07-03 |
EP1494661A1 (en) | 2005-01-12 |
US20030195167A1 (en) | 2003-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008526861A (ja) | 炎症性障害を治療するための薬剤併用療法および医薬組成物 | |
SK6212003A3 (en) | Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia | |
US20080161348A1 (en) | Ptx3-gene expression inhibitor | |
US20070003636A1 (en) | Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent | |
US20060111436A1 (en) | Compositions and treatments for modulating kinase and/or HMG-CoA reductase | |
WO2005115397A2 (en) | Compositions and treatments for modulating kinase and/or hmg-coa reductase | |
US20150272944A1 (en) | Novel triglyceride reducing agent | |
JP4287750B2 (ja) | 糸球体疾患治療剤 | |
US20100063070A1 (en) | Combination for use in the treatment of inflammatory disorders | |
US20040087597A1 (en) | Preventives and remedies for complications of diabetes | |
JP4719572B2 (ja) | Lklf/klf2遺伝子発現促進剤 | |
JP2010523486A (ja) | 炎症疾患の治療において使用するための新規な組み合わせ | |
AU2004233693B2 (en) | Adiponectin production enhancer | |
JP4187141B2 (ja) | 新規なトロンボモジュリン発現促進剤 | |
WO2012046772A1 (ja) | リンパ浮腫予防治療剤 | |
EP1719524B1 (en) | Nuclear transfer promoter for rac protein and method of screening the same | |
EP2033646A1 (en) | Prophylactic and/or therapeutic agent for rheumatoid arthritis | |
JP2005232150A (ja) | アディポネクチン産生増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051216 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090717 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091110 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091111 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121120 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121120 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131120 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |